2 reports of this reaction
1.6% of all AVOBENZONE, HOMOSALATE, OCTOCRYLENE reports
#20 most reported adverse reaction
SLEEP DISORDER is the #20 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTOCRYLENE, manufactured by CVS. There are 2 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTOCRYLENE to SLEEP DISORDER. This represents approximately 1.6% of all 123 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTOCRYLENE who experience sleep disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SLEEP DISORDER is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to sleep disorder, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTOCRYLENE:
The following drugs have also been linked to sleep disorder in FDA adverse event reports:
SLEEP DISORDER has been reported as an adverse event in 2 FDA reports for AVOBENZONE, HOMOSALATE, OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SLEEP DISORDER accounts for approximately 1.6% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTOCRYLENE, making it a notable side effect.
If you experience sleep disorder while taking AVOBENZONE, HOMOSALATE, OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.